Loading clinical trials...
Loading clinical trials...
A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to standard-dose treatment, in treatment-naive participants with CHC, genotype 1 infection.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Buenos Aires, Argentina
Buenos Aires, Argentina
La Plata, Argentina
Rosario, Argentina
Adelaide, Australia
Adelaide, Australia
Bankstown, Australia
Box Hill, Australia
Brisbane, Australia
Cottontree, Australia
Start Date
August 1, 2004
Primary Completion Date
March 1, 2009
Completion Date
March 1, 2009
Last Updated
August 4, 2016
896
ACTUAL participants
PEG-IFN alfa-2a
DRUG
Ribavirin
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT05870969
NCT03987503
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04382404